EP3730138A4 - Arzneimittel mit kombination aus sepetaprost und rho-kinase-inhibitor - Google Patents
Arzneimittel mit kombination aus sepetaprost und rho-kinase-inhibitor Download PDFInfo
- Publication number
- EP3730138A4 EP3730138A4 EP18891292.7A EP18891292A EP3730138A4 EP 3730138 A4 EP3730138 A4 EP 3730138A4 EP 18891292 A EP18891292 A EP 18891292A EP 3730138 A4 EP3730138 A4 EP 3730138A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sepetaprost
- rho
- medicament
- combination
- kinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title 1
- BKVUSNOUTQMSBE-XCMGCKIWSA-N propan-2-yl 4-[(3s,5ar,6r,7r,8as)-6-[(e,3r)-4-(2,5-difluorophenoxy)-3-hydroxybut-1-enyl]-7-hydroxy-3,4,5,5a,6,7,8,8a-octahydro-2h-cyclopenta[b]oxepin-3-yl]butanoate Chemical compound C([C@H](O)/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1CC[C@@H](CO2)CCCC(=O)OC(C)C)OC1=CC(F)=CC=C1F BKVUSNOUTQMSBE-XCMGCKIWSA-N 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
- 229950000863 sepetaprost Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP24153812.3A EP4338751A3 (de) | 2017-12-21 | 2018-12-20 | Arzneimittel mit einer kombination aus sepetaprost und rho-assoziiertem coiled-coil mit einem proteinkinasehemmer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017244847 | 2017-12-21 | ||
JP2018180658 | 2018-09-26 | ||
PCT/JP2018/046970 WO2019124488A1 (ja) | 2017-12-21 | 2018-12-20 | セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP24153812.3A Division EP4338751A3 (de) | 2017-12-21 | 2018-12-20 | Arzneimittel mit einer kombination aus sepetaprost und rho-assoziiertem coiled-coil mit einem proteinkinasehemmer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3730138A1 EP3730138A1 (de) | 2020-10-28 |
EP3730138A4 true EP3730138A4 (de) | 2021-08-25 |
EP3730138B1 EP3730138B1 (de) | 2024-02-14 |
Family
ID=66993448
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP24153812.3A Pending EP4338751A3 (de) | 2017-12-21 | 2018-12-20 | Arzneimittel mit einer kombination aus sepetaprost und rho-assoziiertem coiled-coil mit einem proteinkinasehemmer |
EP18891292.7A Active EP3730138B1 (de) | 2017-12-21 | 2018-12-20 | Kombination von sepetaprost und ripasudil zur verwendung in der prophylaxe oder behandlung von glaukom oder okulärer hypertension |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP24153812.3A Pending EP4338751A3 (de) | 2017-12-21 | 2018-12-20 | Arzneimittel mit einer kombination aus sepetaprost und rho-assoziiertem coiled-coil mit einem proteinkinasehemmer |
Country Status (9)
Country | Link |
---|---|
US (2) | US11446273B2 (de) |
EP (2) | EP4338751A3 (de) |
JP (2) | JPWO2019124488A1 (de) |
KR (1) | KR20200103042A (de) |
CN (1) | CN111479568A (de) |
CA (1) | CA3086457A1 (de) |
ES (1) | ES2972934T3 (de) |
TW (2) | TWI788484B (de) |
WO (1) | WO2019124488A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技(上海)有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0286903B2 (de) | 1987-04-03 | 2000-03-29 | The Trustees Of Columbia University In The City Of New York | Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes |
US4952581A (en) | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
AU720326B2 (en) | 1995-12-21 | 2000-05-25 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
CA2263425C (en) | 1996-08-12 | 2008-09-30 | Yoshitomi Pharmaceutical Industries Ltd. | Pharmaceutical agent containing rho kinase inhibitor |
JP4212149B2 (ja) | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
AU5198199A (en) | 1998-08-17 | 2000-03-06 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
JP4342704B2 (ja) | 2000-07-21 | 2009-10-14 | 富士フイルム株式会社 | 液晶分子の配向方法 |
US20030018079A1 (en) | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
HN2002000067A (es) | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
TWI336328B (en) | 2001-03-23 | 2011-01-21 | Bayer Healthcare Llc | Rho-kinase inhibitors |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
JP4017921B2 (ja) | 2002-06-12 | 2007-12-05 | 高砂熱学工業株式会社 | 暖房室内の空気循環装置 |
JP4128038B2 (ja) | 2002-07-10 | 2008-07-30 | 富士フイルム株式会社 | 電子ペーパー |
JP4482726B2 (ja) * | 2002-08-29 | 2010-06-16 | 参天製薬株式会社 | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
AU2003257588A1 (en) | 2002-08-29 | 2004-03-19 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
WO2004045644A1 (ja) | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
TWI367098B (en) | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
EP1792622A1 (de) * | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Antiproliferative Kombinationstherapie mit einem Platin enthaltenden chemotherapeutischen Mittel und EGFR-Inhibitoren oder Pyrimidinanaloga |
EP2127638A1 (de) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom |
JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
JP2010113957A (ja) | 2008-11-06 | 2010-05-20 | Ntt Docomo Inc | コネクタ |
HUE026742T2 (en) | 2009-03-30 | 2016-07-28 | Ube Industries | A pharmaceutical composition for the treatment or prevention of glaucoma |
JP2012525386A (ja) | 2009-05-01 | 2012-10-22 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 疾患の治療のための二重機構阻害剤 |
JP2011013651A (ja) | 2009-07-03 | 2011-01-20 | Mitsumasa Maeda | フレキシブルディスプレイのれん |
EP2460801B1 (de) | 2009-07-28 | 2014-06-25 | ONO Pharmaceutical Co., Ltd. | Bizyklische verbindung und ihre verwendung für medizinische zwecke |
US9029574B2 (en) | 2011-01-27 | 2015-05-12 | Ono Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
ES2684351T3 (es) * | 2011-02-04 | 2018-10-02 | Kowa Co., Ltd. | Terapia farmacológica para prevenir o tratar glaucoma |
-
2018
- 2018-12-20 EP EP24153812.3A patent/EP4338751A3/de active Pending
- 2018-12-20 WO PCT/JP2018/046970 patent/WO2019124488A1/ja unknown
- 2018-12-20 ES ES18891292T patent/ES2972934T3/es active Active
- 2018-12-20 TW TW107146097A patent/TWI788484B/zh active
- 2018-12-20 CN CN201880081551.1A patent/CN111479568A/zh active Pending
- 2018-12-20 JP JP2019560556A patent/JPWO2019124488A1/ja active Pending
- 2018-12-20 TW TW111150919A patent/TWI833535B/zh active
- 2018-12-20 CA CA3086457A patent/CA3086457A1/en active Pending
- 2018-12-20 KR KR1020207020813A patent/KR20200103042A/ko unknown
- 2018-12-20 EP EP18891292.7A patent/EP3730138B1/de active Active
- 2018-12-20 US US16/955,857 patent/US11446273B2/en active Active
-
2022
- 2022-08-15 US US17/887,854 patent/US20220387372A1/en active Pending
-
2023
- 2023-06-02 JP JP2023091268A patent/JP2023110030A/ja active Pending
Non-Patent Citations (3)
Title |
---|
EYDIE MILLER ELLIS ET AL: "Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study", BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 101, no. 6, 20 September 2016 (2016-09-20), GB, pages 796 - 800, XP055538363, ISSN: 0007-1161, DOI: 10.1136/bjophthalmol-2016-309023 * |
LEWIS RICHARD A ET AL: "Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension", BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 100, no. 3, 1 March 2016 (2016-03-01), GB, pages 339 - 344, XP055824829, ISSN: 0007-1161, DOI: 10.1136/bjophthalmol-2015-306778 * |
LOUISE J LU ET AL: "Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma", THE YALE JOURNAL OF BIOLOGY AND MEDICINE, vol. 90, no. 1, 1 March 2017 (2017-03-01), US, pages 111 - 118, XP055765723, ISSN: 0044-0086 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019124488A1 (ja) | 2019-06-27 |
CA3086457A1 (en) | 2019-06-27 |
ES2972934T3 (es) | 2024-06-17 |
US11446273B2 (en) | 2022-09-20 |
EP4338751A2 (de) | 2024-03-20 |
US20220387372A1 (en) | 2022-12-08 |
TWI833535B (zh) | 2024-02-21 |
EP3730138A1 (de) | 2020-10-28 |
CN111479568A (zh) | 2020-07-31 |
TW201927298A (zh) | 2019-07-16 |
EP3730138B1 (de) | 2024-02-14 |
KR20200103042A (ko) | 2020-09-01 |
TW202320747A (zh) | 2023-06-01 |
JP2023110030A (ja) | 2023-08-08 |
US20200316009A1 (en) | 2020-10-08 |
EP4338751A3 (de) | 2024-05-22 |
JPWO2019124488A1 (ja) | 2020-12-17 |
TWI788484B (zh) | 2023-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3700527A4 (de) | Papd5-inhibitoren und verfahren zur verwendung davon | |
EP3684361A4 (de) | Substituierte inhibitoren von menin-mll und verfahren zur verwendung | |
IL276095A (en) | gcn2 inhibitors and their uses | |
EP3703806A4 (de) | Hämostasevorrichtungen und verfahren zur verwendung | |
IL276147A (en) | GCN2 inhibitors and uses thereof | |
EP3658557A4 (de) | Tyk2-inhibitoren und verwendungen davon | |
EP3429591A4 (de) | Substituierte inhibitoren von menin-mll und verfahren zur verwendung | |
EP3307728A4 (de) | Kombinationstherapie von transkriptionshemmern und kinasehemmern | |
EP3471727A4 (de) | Cxcr4-inhibitoren und verwendungen davon | |
EP3454945A4 (de) | Ash11-inhibitoren und verfahren zur behandlung damit | |
EP3389658A4 (de) | Glycosidasehemmer und verwendungen davon | |
EP3472129A4 (de) | Cxcr4-inhibitoren und verwendungen davon | |
EP3510040A4 (de) | Ektonukleotidasehemmer und verfahren zur verwendung davon | |
EP3670513A4 (de) | Fgfr-inhibitor und medizinische anwendung davon | |
EP3558998A4 (de) | Ektonukleotidasehemmer und verfahren zur verwendung davon | |
EP3548683A4 (de) | Anordnung zur umkippvorbeugung eines möbelstücks und möbelstück mit solch einer anordnung | |
EP3589319A4 (de) | Glycaninteragierende verbindungen und verfahren zur verwendung | |
EP3281942A4 (de) | B-lactamase-hemmer und verwendung davon | |
EP3471726A4 (de) | Cxcr4-inhibitoren und verwendungen davon | |
EP3572400A4 (de) | Ezh2-inhibitor und verwendung davon | |
LT3532459T (lt) | Lsd1 inhibitoriai ir jų medicininis panaudojimas | |
EP3592731A4 (de) | Inhibitoren von malt1 und verwendungen davon | |
EP3710430A4 (de) | Acss2-hemmer und verfahren zur verwendung | |
EP3681499A4 (de) | Verbindungen als ras-inhibitoren und ihre verwendung | |
EP3706737A4 (de) | Ash11-inhibitoren und verfahren zur behandlung damit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200702 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40029829 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210726 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/558 20060101AFI20210720BHEP Ipc: A61K 31/335 20060101ALI20210720BHEP Ipc: A61K 31/472 20060101ALI20210720BHEP Ipc: A61K 31/551 20060101ALI20210720BHEP Ipc: A61K 45/00 20060101ALI20210720BHEP Ipc: A61P 9/12 20060101ALI20210720BHEP Ipc: A61P 27/02 20060101ALI20210720BHEP Ipc: A61P 27/06 20060101ALI20210720BHEP Ipc: A61P 43/00 20060101ALI20210720BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref document number: 602018065361 Country of ref document: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031335000 Ipc: A61K0031558000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20230313BHEP Ipc: A61K 31/335 20060101ALI20230313BHEP Ipc: A61K 31/472 20060101ALI20230313BHEP Ipc: A61K 45/00 20060101ALI20230313BHEP Ipc: A61P 9/12 20060101ALI20230313BHEP Ipc: A61P 27/02 20060101ALI20230313BHEP Ipc: A61P 27/06 20060101ALI20230313BHEP Ipc: A61P 43/00 20060101ALI20230313BHEP Ipc: A61K 31/551 20060101ALI20230313BHEP Ipc: A61K 31/558 20060101AFI20230313BHEP |
|
INTG | Intention to grant announced |
Effective date: 20230406 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20230913 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231220 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018065361 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2972934 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240617 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20240214 |